News Character raises $93m for eye drugs, plus other financings Recent financings in the biotech space include rounds for Character Bio, Tempero, Epicrispr, Hillstar Bio, and Ampersand Biomedicines.
News Phase 3 readout puts Opthea at risk of insolvency After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.
News Augustine decloaks with $85m for nerve disease programme Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.
News Sofinnova closes new fund and backs a trio of new biotechs Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
News Insilico raises $110m for AI-designed drug pipeline Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery operations.
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face